A New Orleans federal appeals court restricted access to mail-order prescriptions of the abortion‑inducing drug mifepristone.
The panel of the 5th U.S. Circuit Court of Appeals, based in New Orleans, will require in-person distribution of the mifipristone at clinics.
The ruling found that the Food and Drug Administration (FDA) regulation that allows prescriptions of the medication that blocks progesterone without meeting with a physician “undermines” the state of Louisiana. In Louisiana, the state considers unborn children to be human beings from the moment of conception and legal persons.
Medication abortions, which rely on mifepristone and misoprostol, accounted for 63% of U.S. abortions in 2023, according to the Guttmacher Institute. The number of actual abortions might be higher due to underreporting, according to the organization, which was affiliated with Planned Parenthood until 2007.
Activists, lawmakers, and state attorneys general have been calling on the FDA to do a safety review of the drug, citing severe risks to women’s health.
A recent study by the Ethics and Public Policy Center (EPPC) found that the removal of in-person visit requirements led to an increase in adverse effects for women having drug-induced abortions. This study is one among several pointing to a higher rate of serious problems.
Multiple other studies have shown high rates of hospitalizations for women taking the abortion pill. “Chemical abortion has a complication rate four times greater than surgical abortion,” according to one study. Another report found that medication abortion complications are often underreported or misclassified.
Leave a Reply
You must be logged in to post a comment.